ArticleClinical kidney journal2026
Association of eplet mismatch load and allograft injury in kidney transplant recipients.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Eplet mismatch load is a molecular measure of donor-recipient histocompatibility that has been associated with alloimmune outcomes after kidney transplantation. However, its relationship with comprehensive markers of early allograft injury remains incompletely defined. Methods: In this single-center retrospective cohort study, we evaluated 657 adult kidney transplant recipients who underwent transplantation between January 2021 and December 2024. Eplet mismatch load was calculated at the HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci using the HLA Eplet Registry. The primary outcome was a composite of early allograft injury, defined as the independent occurrence of de novo donor-specific antibodies, histologic rejection, molecular rejection assessed by the Molecular Microscope Diagnostic System, or elevation of donor-derived cell-free DNA within the first year after transplantation. Results: During the first post-transplant year, 248 patients (37.7%) experienced the primary outcome. Median eplet mismatch load was significantly higher among patients with the primary outcome across most HLA loci. In adjusted Cox regression models, higher eplet mismatch load (per one-eplet increase) was independently associated with increased risk of the primary outcome for HLA-DRB1 (hazard ratio 1.025; 95% confidence interval 1.011-1.038), HLA-DQA1 (hazard ratio 1.075; 95% confidence interval 1.025-1.127), and HLA-DQB1 (hazard ratio 1.038; 95% confidence interval 1.020-1.057). Compared with zero eplet mismatch, high-risk class II eplet mismatch categories were associated with approximately two- to three-fold higher risk of early allograft injury. Associations for class I loci were weaker and pattern-dependent after adjustment. Conclusion: In conclusion, a higher class II HLA-eplet mismatch load was independently associated with early kidney allograft injury during the first post-transplant year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.